FDA Expands Voluntary Recall of Soliris After Recieving Reports of Contamination
December 17, 2013
Manufacturers of the medications Americans use have a responsibility to ensure the safety of the drugs they release to consumers. The Drug Injury Attorneys with Ferrer, Poirot & Wansbrough explain that failure to do so can result in costly recalls in order to ensure defective drugs don’t harm patients.
The U.S. Food and Drug Administration recently announced an update to such a recall regarding Alexion Pharmaceutical Inc.’s medication, Soliris ® (eculizumab) Concentrated Solution for Intravenous Infusion. According to a Press Release from the agency, certain lots of the medication contain visible particles. Any patient receiving the affected medications faces an increased risk of immunogenicity or thromboembolic events.
Experts say the particles in the affected lots of medications could cause blockages in the blood vessels of the patient, which could cause death.
The manufacturer of the drugs has already asked all distributors in possession of the affected medications to return them immediately, but have now asked all hospitals and patients who have these particular drugs to return them as well. Anyone who experiences a Defective Drug Injury associated with this product have also been instructed to report the incident to the FDA immediately.
The attorneys with Ferrer, Poirot & Wansbrough recognize the dangers using a defective medication can pose and would also encourage anyone who has been harmed by a drug prescribed to them by a doctor to discuss their legal rights with a lawyer as well.